Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial.

Publication

Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial.

Journal Paper/Review - Feb 27, 2022

Mahfoud Felix, Farah Ahmed, Ohlow Marc-Alexander, Mangner Norman, Wöhrle Jochen, Möbius-Winkler Sven, Weilenmann Daniel, Leibundgut Gregor, Cuculi Florim, Gilgen Nicole, Kaiser Christoph, Cattaneo Marco, Scheller Bruno, Jeger Raban V

Citation

Mahfoud F, Farah A, Ohlow M, Mangner N, Wöhrle J, Möbius-Winkler S, Weilenmann D, Leibundgut G, Cuculi F, Gilgen N, Kaiser C, Cattaneo M, Scheller B, Jeger R. Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial. Clin Res Cardiol 2022; 111:806-815.

Type

Journal Paper/Review (English)

Journal

Clin Res Cardiol 2022; 111

Publication Date

Feb 27, 2022

Issn Electronic

1861-0692

Pages

806-815

Brief description/objective

Data on the safety and efficacy of drug-coated balloon (DCB) compared to drug-eluting stent (DES) in patients with chronic kidney disease (CKD) are scarce, particularly at long term. This pre-specified analysis aimed to investigate the 3-year efficacy and safety of DCB versus DES for small coronary artery disease (< 3 mm) according to renal function at baseline.